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Abstract
Staphylococcus aureus is an important cause of bacteremia, and S. aureus bacteremia con‐
stitutes a serious condition with high morbidity and mortality, secondary to multiple 
complications including infective endocarditis and embolization. The incidence of bac‐
teremia with S. aureus is increasing with more frequent use of medications that lower 
immune system response, and with the utilization of more invasive medical procedures. 
In addition, the emergence of resistant S. aureus isolates is becoming more common and 
can negatively affect the outcome of an individual if not diagnosed and managed prop‐
erly. Health care workers encounter S. aureus bloodstream infections on a routine basis, 
and in certain situations, it becomes a very challenging infection to control. Because of 
the impact this entity has on health care costs and the increased use of resources, it is 
necessary to highlight the causes, clinical presentation, associated complications, and 
treatment measures. In this chapter, we will cover each of these points, with somewhat 
more emphasis on methicillin‐resistant S. aureus that is prevalent in both community 
and hospital settings and is more commonly associated with worsening prognosis and 
higher mortality.
Keywords: Staphylococcus aureus, Bacteremia, Sepsis, methicillin susceptible, methicillin 
resistant, community acquired, hospital acquired
1. Staphylococcus aureus infections: introduction
Staphylococcus aureus is a Gram‐positive staphylococci that can exist commensally with 
humans as a colonizer but can also exist as a pathogen. It is a major pathogen in bacteremia 
whether community acquired or hospital acquired. It has proven its versatility by continu‐
ing to be an important infectious pathogen that has contributed to increasing morbidity 
and mortality of patients over the years. Despite the advances in antibiotic therapy target‐
ing this pathogen, S. aureus remains a multipotent organism that causes infection using 
toxin production and nontoxin‐mediated pathways. This organism causes a wide array of 
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infections, from a simple skin infection to more dangerous situations such as bacteremia, 
endocarditis, pneumonia, bone and joint infections, and many others that may jeopardize 
the life of the patient. Bacteremia is one major cause of morbidity in both the inpatient 
and outpatient  setting, and S. aureus is notorious for causing invasive infections that lead 
to bacteremia.
Patients with S. aureus bacteremia can be at risk for many complications that may increase 
morbidity, with mortality rates of 20–40% that have been described. The higher the level of 
resistance, the higher the mortality rates. This is why methicillin‐resistant S. aureus (MRSA) 
is expected to have a higher morbidity/morality, longer hospital stays, and higher health 
care costs when compared with methicillin‐sensitive S. aureus (MSSA) bacteremia [1]. Also, 
in cases of infection with MRSA, there is a higher rate of treatment failure that may include 
death within 30 days of receiving therapy, persistent positive blood cultures for more than 
10 days after therapy, or recurrence of septicemia within 60 days after  finishing therapy.
2. S. aureus colonization
S. aureus is a part of the normal human flora; up to 50% of healthy individuals may be persis‐
tently colonized with it. Colonization with S. aureus can be persistent in up to 20% of cases, 
intermittent in 60%, and always absent in up to 20% of people. In a study performed on the 
general US population that looked at colonization rates in the nares with S. Aureus, it was 
found that the prevalence of MRSA colonization was 0.8% between 2001 and 2002, and went 
up to 1.5% between 2003 and 2004. The anterior nares is felt to be the major site of S. aureus 
colonization, but some people can be colonized with S. aureus outside the nares in areas such 
as the throat, axilla, inguinal region, and perirectal area. Several conditions may increase the 
rate of colonization such as diabetes mellitus, HIV infection, underlying skin diseases, and 
end stage renal disease requiring hemodialysis. Colonization typically precedes S. aureus 
infection. These conditions can place the subject at a higher risk of invasive staphylococcal 
infections such as bacteremia, which is why much of infection control and prevention efforts 
target colonization with S. aureus.
Nasal carriage of S. aureus colonization has been associated with the development of infec‐
tions. A substantial proportion of cases of S. aureus bacteremia appear to be of endog‐
enous origin as they originate from colonies in the nasal mucosa. This is one reason why 
strategies to prevent systemic S. aureus infections by eliminating nasal carriage need to 
be supported.
3. Epidemiology
Since methicillin‐resistant S. aureus constitutes a major burden on health care systems we 
will focus mainly on it. There are several terms for classifying MRSA infections, namely 
bacteremia. The first category is the health care–associated MRSA (also called nosocomial) 
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that occurs more than 48 hours into hospitalization. The second category is community‐
onset health care–associated MRSA, which includes two factions: (1) patients in whom 
infection occurs less than 48 hours into hospitalization and (2) patients in the commu‐
nity who have had a prior hospitalization in the last 12 months (including for surgery 
or dialysis) or those who are residents of long‐term care facilities. The third category is 
community‐associated MRSA infections occurring outside of health care settings among 
individuals who do not have prior health care exposures. Several outbreaks of MRSA have 
occurred in the community without exposure to health care facilities. This reflects a great 
change in the epidemiology of MRSA‐related infections. Once solely a hospital pathogen 
and only seen among individuals with prior health care exposures, now MRSA is seen in 
populations without health care exposures. Poor hygiene conditions, close contact, con‐
taminated material, and damaged skin were found to be some of the risk factors for spread 
of MRSA infection in the community. In the United States, the most common MRSA com‐
munity‐acquired strain is the USA300 strain based on pulsed‐field gel electrophoresis. This 
community‐based clone mostly causes skin and soft tissue infections, but it may cause 
more invasive infections such as bacteremia in 5–10% of people. This clone is causing more 
nosocomial infections as well.
Besides being an important cause of community‐acquired bacteremia such as in cases of 
intravenous drug use leading to endocarditis, or cases of intravenous home infusion therapy, 
S. aureus is a leading cause of nosocomial bacteremia. It ranks second after coagulase negative 
staphylococci as a cause of primary bacteremia. In the hospital setting, a higher prevalence 
of methicillin‐resistant isolates is seen. Most of the time, bacteremia develops from S. aureus 
strains colonizing the host; however, this infection can be transmitted through contact with 
other colonized individuals or contaminated surfaces such as hands of health care workers 
or environmental spaces. Spread of staphylococci in aerosols of respiratory secretions from 
colonized patients has also been reported.
4. S. aureus virulence factors leading to bacteremia
In observing individual responses to MRSA infection, some hosts become severely ill while 
others have only mild symptoms. It is unclear why certain factors are directly linked to this 
discrepancy in response. There are several virulence factors of S. aureus that may be struc‐
tural and secreted products that could cause the pathogenesis of the disease with S. aureus. 
Microbial surface components recognizing adhesive matrix molecules (MSCRAMMs) are 
surface proteins that mediate adherence of S. aureus to host tissues. These molecules bind 
molecules belonging to different surfaces such as fibronectin, collagen, and fibrinogen. The 
MSCRAMMs help establish invasive and serious infections like endovascular infections, 
bone and joint infections, and prosthetic‐device infections. Figure 1 represents a schema 
of the structural and secreted products that S. aureus uses in order to achieve a high viru‐
lence level, and serious infections like blood stream infection. Table 1 listed a few selected 
 virulence factors [2].
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Figure 1. Pathogenic factors of Staphylococcus aureus with structural and secreted products both playing roles as 
virulence factors. (A) Surface and secreted proteins. (B and C) Cross sections of the cell envelope. TSST‐1, toxic shock 
syndrome toxin‐1. Source: With permission from the Massachusetts Medical Society. Copyright 1998 Massachusetts 
Medical Society.
Type of virulence factors Selected factorsa Associated clinical syndromes
Involved in attachment MSCRAMMs (e.g., clumping factors, 
fibronectin‐binding proteins, collagen, and 
bone sialoprotein‐binding proteins)
Endocarditis, osteomyelitis, septic 
arthritis, and prosthetic‐device and 
catheter infections
Involved in persistence Biofilm accumulation (e.g., polysaccharide 
intercellular adhesion), small‐colony variants, 
and intracellular persistence
Relapsing infections, cystic fibrosis, 




Leukocidins (e.g., PVL and γ‐toxin), capsular 
polysaccharides (e.g., 5 and 8), protein A, 
CHIPS, Eap, and phenol‐soluble modulins
Invasive skin infections and necrotizing 
pneumonia (CA‐MRSA strains that 
cause these are often associated with 
PVL) abscesses (associated with capsular 
polysaccharides)
Involved in tissue 
invasion/penetration
Proteases, lipases, nucleases, hyaluronate 
lyase, phospholipase C, and metalloproteases 
(elastase)
Tissue destruction and metastatic 
infections
Involved in toxin‐mediated 
disease and/or sepsis
Enterotoxins, toxic shock syndrome 
toxin‐1, exfoliative toxins A and B, α‐toxin, 
peptidoglycan, and lipoteichoic acid
Food poisoning, toxic shock syndrome, 
scalded skin syndrome, bullous 
impetigo, and sepsis syndrome
With poorly defined role in 
virulence
Coagulase, ACME, and bacteriocin
Table 1. Selected Staphylococcus aureus virulence factors.
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5. Pathogenicity
Several mechanisms lead to blood stream infection with S. aureus. After adhering to tissues 
or prosthetic materials, S. aureus is capable of growing in various ways. It can evade host 
defenses and the activity of antibiotics by forming biofilms on host and prosthetic surfaces. 
Additionally, S. aureus may escape the defense mechanisms by surviving inside several types 
of cells (such as endothelial cells) as in the situation of bacteremia and endocarditis. Another 
mechanism of survival is that S. aureus can form small‐colony variants (SCVs) that can hide in 
host cells thus keeping them protected against defense mechanisms and leading to persistent 
and recurrent infection. The production of an antiphagocytic microcapsule is another method 
of defense escape used by S. aureus and can cause abscess formation. S. aureus can further 
halt host defenses by blunting neutrophil extravasation and chemotaxis to the infected area 
by producing chemotaxis inhibitory protein. Moreover, it produces leukocidins that destroy 
leucocytes by inflicting holes in the cell membrane.
Additional methods that help S. aureus in creating invasive blood stream infection exist and 
include the secretion of numerous enzymes that hydrolyzes tissues. This causes invasion, destruc‐
tion and further spread of the pathogen to distant organs via the blood stream. Septic shock can 
thus result through the activation of the individual's immune system and coagulation pathways.
Pathogenesis of S. aureus is also affected by regulation of the expression of virulence factors. 
It appears that expression of these factors in a coordinated manner reduces the metabolic 
demands of the pathogen. Thus, MSCRAMM proteins that get secreted early in the infectious 
process help the establishment of the infection in tissue sites, while the later production of 
toxins facilitates the spread of the infection. The accessory gene regulator (agr) is a quorum‐
sensing system that plays a critical role in the regulation of staphylococcal virulence.
Besides virulence factors of S. aureus, it appears that patients were sicker when they devel‐
oped an infection in the setting of negative colonization status. Noncarriers of the organism 
seem to have less protective immunity than those who are carriers. The formation of antibod‐
ies may also protect against the development of toxic shock syndrome.
Based on the above fact, S. aureus has many mechanisms to produce disease, namely bactere‐
mia, while evading host defenses.
6. Bacteremia caused by S. aureus
Bacteremia is defined as the presence of bacteria in normally sterile blood. Typically more 
than one bottle in the set will be positive for growth; however, only one positive bottle is 
needed to diagnose bacteremia. Risk factors associated with S. aureus bacteremia include 
the presence of prosthetic devices, surgical site infections, or skin conditions such as chronic 
ulceration, injection drug use (IDU), and host factors that incur predisposition to recurrent 
infections. Prosthetic devices include any intravascular catheter such as hemodialysis catheter 
or central venous catheter. Patients on hemodialysis are at a higher risk for  staphylococcal 
endocarditis and constitute a relatively new at‐risk group. Other factors include defects of 
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 polymorphonuclear leukocytes and congenital syndromes that are associated with more 
risk of S. aureus infections, such as the cases of neutropenia, chronic granulomatous disease, 
as well as Job’s, Chediak‐Higashi, and Wiskott‐Aldrich [3].
Clinical manifestations of S. aureus bacteremia typically involve systemic responses such as fever 
and hypotension. When bacteremia occurs secondarily to infection at a primary site, clinical 
symptoms associated with that organ system may also be present. Cellulitis, chronic ulceration, 
or trauma to skin and soft tissue may serve as portals of entry for the bacteria and the primary 
source of a S. aureus bacteremia. Tenderness or erythema surrounding a vascular catheter may 
also serve as a clinical manifestation of underlying bacteremia [4], though absence does not rule 
out the diagnosis. Patients with S. aureus pneumonia can develop bacteremia and have accompa‐
nying upper respiratory symptoms. S. aureus bacteriuria without the presence of a urinary cath‐
eter may be an indicator of S. aureus bacteremia [5]. S. aureus meningitis, though less common, 
may also occur in the setting of complication due to S. aureus  bacteremia [6] and in addition to 
fever can demonstrate confusion and nuchal rigidity associated with acute bacterial meningitis.
Clinical approach to a patient with S. aureus bacteremia should include a detailed history, thor‐
ough physical exam, and if required, additional imaging with possible infectious disease con‐
sultation. History should involve questions as to the presence or absence of potential portals of 
entry such as wounds and also determine the presence of prosthetic devices including hardware 
(orthopedic or cardiac) and intravascular catheters. Questions related to localization of pain 
may help determine if metastatic spread has occurred such as in cases of vertebral osteomyeli‐
tis/diskitis or endocarditis. Physical exam should include an extensive evaluation of the skin 
and mucous membranes to look for sites of bacterial entry. Cardiac evaluation should assess 
for the presence of murmurs associated with infective endocarditis. Other stigmata of endocar‐
ditis should be sought through fundoscopic exam and exam of the digits for the appearance 
of emboli in skin. Baseline mental status should be noted and carefully monitored for signs of 
deterioration which may be concomitant with development of additional complications.
Complications of S. aureus bacteremia range from colonization after a treatment to infective 
endocarditis. Infective endocarditis is one of the most severe complications, with S. aureus 
now recognized as the most common cause in the industrialized world [7]. Pathogenesis is 
due to a combination of adhesion factors (as discussed earlier) on the surface of S. aureus 
and bacterial‐induced platelet aggregation, which cause adhesion damage to heart valves [8]. 
Risk factors for IE in the setting of S. aureus bacteremia include prosthetic heart valve or pre‐
disposing cardiac abnormalities, IVDU, intravascular catheter infection, or persistent bac‐
teremia [9]. Specific clinical manifestations associated with S. aureus infective endocarditis 
include sepsis syndrome involving fever, tachycardia, and hypotension, cardiac failure due to 
valve destruction, and sequelae from septic emboli. Within the heart, once S. aureus adheres 
to and colonizes the valve its intrinsic procoagulant activity triggers deposition of platelets 
and fibrin which leads to the formation of a vegetation. The structural abnormality is typically 
associated with regurgitation, and if untreated can progress to cardiac failure. Transthoracic 
 echocardiography should be used as the initial diagnostic test in a patient with suspected 
endocarditis, as its specificity approaches 100% [10], however, specificity is lower being at 
most 75%. Transthoracic echocardiography is not 100% specific for infective endocarditis due 
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to potential false positives, however, given a sensitivity greater than 90%, it is the better of 
the two for identification of valvular vegetations. Vascular phenomena occur when septic 
emboli dislodge from the vegetation and occlude arteries in the periphery as well as centrally 
affecting vital organs. Peripheral manifestations including skin lesions (Janeway spots, Osler's 
nodes) and retinal lesions (Roth's spots), while splenic vein thrombosis can lead to infarction 
of the spleen. Neurological complications include cerebral infarctions, intracerebral or sub‐
arachnoid  hemorrhage, meningitis, cerebritis, and encephalomalacia.
7. Bacteremia treatment
Treatment of S. aureus bacteremia should first be approached by seeking out a potential focus 
of infection and determining whether or not it can be removed. Though no specific guidelines 
exist regarding duration of treatment, the general consensus advocates a 14‐day treatment 
course for S. aureus bacteremia in cases where the source such as an intravascular catheter or 
prosthetic device can be removed, or an abscess can be drained [11]. In cases where removal 
of an intravascular catheter is not possible, antibiotic lock therapy may be used in an attempt 
to salvage the line, which includes filling the catheter lumen with high concentrations of 
antibiotics and leaving them in place for several hours to days [12]. Longer treatment courses 
extending for 4–6 weeks are required for deeper wound infections such as endocarditis and 
osteomyelitis. Methicillin‐resistant S. aureus coverage should be included in empiric therapy 
with de‐escalation to a beta‐lactam agent if methicillin‐susceptible S. aureus is later identified.
Once S. aureus susceptibility is determined, antibiotic therapy may be directed toward either 
MSSA or MRSA. Beta‐lactams such as penicillins and cephalosporins, and if needed, glyco‐
peptides, are antibiotics classes used for the treatment of MSSA. Beta‐lactams inhibit bacterial 
cell wall assembly by binding to membrane bound enzymes called penicillin‐binding proteins 
that perform cross‐linking. The beta‐lactam ring binds to the penicillin‐binding proteins and 
prevents the cross‐linking component of cell wall assembly, causing cell death via autolysis 
of osmotic instability [13]. In cases where beta‐lactams cannot be used to treat MSSA, such as 
with history of anaphylaxis to penicillin, the class of antibiotics known of as glycopeptides 
(which includes vancomycin) may be used. It should not be used as primary treatment for 
MSSA, however, if drug intolerance is not an issue.
Since MRSA bacteremia constitutes a great deal of infection in this day and constitutes a major 
cause of increasing morbidity and mortality, we decided to elaborate more about its treatment 
in different settings and to discuss the newer treatment options that are available.
8. Management of MRSA bacteremia and infective endocarditis in adults
MRSA was described in 1961, shortly after methicillin was introduced. Unlike penicillin 
 resistance, which is achieved via the bacteria‐produced enzyme penicillinase, methicillin 
resistance is mediated by a newly acquired penicillin‐binding protein (called PBP2A) and 
encoded for by the mecA gene. The MecA gene is located on a mobile genetic element called 
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staphylococcal chromosome cassette (SCCmec) [14]. If methicillin‐resistant S. aureus bacte‐
remia is identified, vancomycin and daptomycin are generally recommended for treatment 
based on current guidelines. Glycopeptides are a class of antibiotics that include vancomycin 
and work by binding to bacterial cell wall precursors and interfering with penicillin‐binding 
protein enzymes, causing cessation of cell wall synthesis and later cell death. Daptomycin 
is a lipopeptide that is approved for the treatment of S. aureus‐complicated skin or soft tis‐
sue infection, bacteremia and right‐sided infective endocarditis [15]. Daptomycin diffuses 
through the peptidoglycan layer of Gram‐positive organisms to the plasma membrane where 
it caused rapid depolarization resulting in the loss of membrane potential leading to loss of 
protein, DNA, and RNA synthesis and resulting in cell death [16].
In the case of uncomplicated bacteremia that is determined by the absence of endocarditis, 
artificial hardware, multiple sites of infection, and for which repeated blood cultures do not 
grow MRSA and patients are clinically well, vancomycin or daptomycin 6 mg/kg/dose IV 
once daily can be given for at least 2 weeks. However, in the case of complicated bacteremia, 
a duration of 4–6 weeks of therapy is recommended, depending on the extent of infection. 
Sometimes, higher dosages of daptomycin at 8–10 mg/kg/dose IV once daily may be needed.
When MRSA bacteremia becomes complicated with infective endocarditis, IV vancomycin 
or daptomycin 6–10 mg/kg/dose IV once daily for 6 weeks is recommended. It is not recom‐
mended to add gentamicin or rifampin to vancomycin for bacteremia or native valve infective 
endocarditis.
It is also important to identify the source and extent of the infection with removal and debride‐
ment or drainage of other sites of infection to decrease the bulk of the infection. Blood cul‐
tures need to be collected every 2–4 days after initial positive cultures until documentation 
of the clearance of bacteremia. And echocardiography is recommended for all adult patients 
with bacteremia to eliminate the possibility of associated endocarditis; transesophageal echo‐
cardiography (TEE) being preferred over transthoracic echocardiography (TTE). In the cases 
of large vegetations that exceed 10 mm in diameter, occurrence of more than one embolic 
event during the first 2 weeks of therapy, severe valvular insufficiency, valvular perforation 
or dehiscence, decompensated heart failure, perivalvular or myocardial abscess, new heart 
block, or persistent fevers or bacteremia, evaluation for replacement of the affected valve 
should be considered in consultation with cardiothoracic surgery.
In conditions that are characterized by MRSA bacteremia complicated with infective endocar‐
ditis of a prosthetic valve, administration of IV vancomycin plus rifampin 300 mg PO/IV every 
8 h for at least 6 weeks plus gentamicin 1 mg/kg/dose IV every 8 h for 2 weeks is recommended, 
along with early evaluation for valve replacement surgery to decrease the risk of embolization.
9. Antimicrobial therapy that may be used for MRSA bacteremia
9.1. Clindamycin
Clindamycin is not specifically approved for treatment of MRSA infection, but it has been 
used for skin infections and invasive susceptible community‐acquired MRSA infections in 
children. It is bacteriostatic and, as such, is not recommended for bacteremia, endovascular 
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infections like infective endocarditis or septic thrombophlebitis. Clindamycin has excellent 
tissue penetration, particularly in bone and abscesses, but has poor penetration into the CSF. 
Community‐acquired MRSA infections are more susceptible to Clindamycin than hospi‐
tal‐acquired isolates. It is important to have a D‐zone test to look for inducible clindamycin 
resistance in erythromycin‐resistant, clindamycin‐susceptible isolates. Side effects include 
diarrhea and Clostridium difficile‐associated disease. Clindamycin is pregnancy category B.
9.2. Daptomycin
This is a lipopeptide class antibiotic that destroys cell membrane function through calcium‐
dependent binding, leading in a bactericidal activity in a concentration‐dependent manner. 
It is FDA approved for adults with S. aureus bacteremia, right‐sided infective endocarditis, and 
complicated skin infections. It is not supposed to be given in nonhematogenous MRSA pneu‐
monia because its activity is inhibited by pulmonary surfactant. The susceptibility breakpoint 
for daptomycin for S. aureus is ≤1 μg/mL. It appears that prior use of vancomycin and elevated 
vancomycin minimal inhibitory concentrations (MICs) has been associated with increases in 
daptomycin MICs and the emergence of nonsusceptible isolates. Monitoring creatinine phos‐
phokinase (CPK) while on daptomycin is necessary to avoid rhabdomyolysis, which is seen 
with higher doses. Therapy with daptomycin may be complicated with daptomycin‐induced 
eosinophilic pneumonia. Daptomycin is pregnancy category B.
9.3. Linezolid
Linezolid is a synthetic oxazolidinone and inhibits initiation of protein synthesis at the 50S 
ribosome. It is FDA‐approved for treatment of skin infections and nosocomial pneumonia 
due to MRSA. It has a 100% oral bioavailability. Resistance to linezolid is rare, but has been 
reported. An outbreak with linezolid‐resistant and methicillin‐resistant S. aureus in an inten‐
sive care unit has been reported in Spain. Resistance to linezolid was mediated by the cfr 
gene, as all isolates ended up carrying this gene. It is not approved for the treatment of MRSA 
bacteremia, although it has been used for this condition on several occasions. Long‐term use 
is not advisable as it may be complicated with hematologic toxicity, thrombocytopenia, ane‐
mia, neutropenia, peripheral and optic neuropathy, and lactic acidosis. Peripheral and optic 
neuropathy may not be reversible. Since it is a weak, nonselective, reversible inhibitor of 
monoamine oxidase, it may cause serotonin syndrome in patients taking concurrent selective 
serotonin‐receptor inhibitors. It is considered pregnancy category C.
9.4. Tedizolid
Tedizolid is an oxazolidinone drug. It has the advantage of oral and parenteral formulations, 
similar to linezolid. It was approved for the treatment of acute bacterial skin and skin struc‐
ture infections in 2014 and is administered once daily. Its use in bacteremia has not been 
recommended at this point.
9.5. Quinupristin‐dalfopristin
Quinupristin‐dalfopristin is constituted of two streptogramin antibiotics and inhibits protein 
synthesis. It is FDA approved for skin and soft tissue infections in adults and children >16 
Staphylococcusaureus Bacteremia in Adults
http://dx.doi.org/10.5772/66225
125
years of age. It has been used as salvage therapy for invasive MRSA infections in the setting 
of vancomycin treatment failure. It can have several side effects such as arthralgias, myalgias, 
and infusion‐related reactions that may limit its use. Quinupristin‐dalfopristin is considered 
pregnancy category B.
9.6. Rifampin
Rifampin is bactericidal against S. aureus and achieves high intracellular levels and good pen‐
etration in biofilms. It cannot, however, be used as monotherapy and is recommended to be 
used in combination with another antibiotic. It can be given at doses ranging from 600 mg 
daily in a single dose or in two divided doses to 900 mg daily in two or three divided doses. 
Rifampin is usually used in the setting of a S. aureus hardware infection.
9.7. Telavancin
Telavancin is an intravenous lipoglycopeptide. It inhibits cell wall synthesis by binding to 
peptidoglycan chain precursors and causing cell membrane depolarization. It has bactericidal 
activity against MRSA, vancomycin intermediate S. aureus (VISA), and vancomycin‐resistant 
S. aureus (VRSA). It is FDA approved for complicated skin and soft tissue infections in adults 
and is pregnancy category C. Nephrotoxicity was more commonly reported among patients 
treated with telavancin than among those treated with vancomycin, however, unlike vancomy‐
cin, there is no need to monitor telavancin levels in the serum. It may be given in bacteremia, 
but would be an off label use.
9.8. Tetracyclines
Doxycycline is a tetracycline that is approved for the treatment of skin and soft tissue infec‐
tions due to S. aureus. There is lack of data to support its use in more invasive infections 
like bacteremia. Tetracycline and doxycycline resistance in CA‐MRSA is associated with tetK 
gene, but does not affect minocycline susceptibility. Minocycline is available in oral and 
parenteral formulations. A newer tetracycline named tigecycline is a glycylcycline and is 
a derivative of the tetracyclines. It is FDA approved in adults for skin and soft tissue infec‐
tions and intraabdominal infections. It has a bacteriostatic activity against MRSA, thus it is 
not used in bacteremia; however, it was found that its use was associated with an increase 
in all‐cause mortality. Tetracyclines are pregnancy category D and are not recommended for 
children <8 years of age due to the potential for tooth enamel discoloration and decreased 
bone growth.
9.9. Trimethoprim‐sulfamethoxazole
TMP‐SMX is not FDA‐approved for the treatment of any staphylococcal infection, but since 
the majority of community‐acquired MRSA strains are susceptible to it in vitro, it has become 
widely used for skin and soft tissue infections. It may also be used in bone and joint infections. 
For more invasive cases such as staphylococcal bacteremia and endocarditis, it can be used, 
though not as a first line drug. In addition, its use in the elderly must be done in conjunction 
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with close monitoring of creatinine and potassium levels. It is not recommended in pregnant 
women in the third trimester (pregnancy category C/D).
9.10. Ceftaroline
Ceftaroline is a fifth‐generation cephalosporin. It is bactericidal against Gram‐positive and 
Gram‐negative pathogens and has activity against MRSA and VISA strains. It is recom‐
mended for skin and skin tissue infections and community‐acquired pneumonia. Its use in 
cases of S. aureus bacteremia is still under investigation.
9.11. Dalbavancin
Dalbavancin is a semisynthetic lipoglycopeptide that inhibits cell wall synthesis. Its half‐life is 
147‐258 hours, which allows use at once weekly dosing. It was approved in 2014 for treatment 
of acute bacterial skin and skin structure infections due to Gram‐positive organisms, includ‐
ing MRSA. It is not yet approved for cases of S. aureus bacteremia.
9.12. Oritavancin
Oritavancin is a semisynthetic glycopeptide that also inhibits cell wall synthesis. Its half‐life is 
100 hours, allowing for single dose therapy. It was approved for treatment of acute bacterial 
skin and skin structure infections in 2014.
9.13. Vancomycin
Vancomycin has been the mainstay of parenteral therapy for MRSA infections; it has slow 
bactericidal activity. There is evidence of emerging resistant strains. Vancomycin kills staphy‐
lococci more slowly than β‐lactams do in vitro and is inferior to β‐lactams for MSSA bactere‐
mia and infective endocarditis. Tissue penetration is highly variable and depends upon the 
degree of inflammation. Vancomycin's minimum inhibitory concentration breakpoints were 
changed in 2006 to improve the detection of intermediate susceptible strains (susceptible: 
MIC of 2 μg/mL or lower; intermediate: MIC of 4–8 μg/mL; and resistant: MIC 16 μg/mL or 
greater). The concept of MIC creep has arisen due to decrease in susceptibility to vancomycin 
among S. aureus isolates. S. aureus strains have been reported to “creep” up and approach 
the breakpoint of 2 with increasing frequency. This has been associated with worse clinical 
outcomes when vancomycin is used as therapy, when the MRSA isolate has a higher MIC to 
vancomycin. Vancomycin is considered pregnancy category C.
10. Management of persistent MRSA bacteremia and vancomycin 
treatment failures in adult patients
In cases of persistent positive blood cultures for S. aureus, it is necessary to look for deep‐seated 
infections and hidden foci that continually send particles of infection into the blood stream. 
Removal of these infectious foci by either drainage or surgical debridement is  recommended. 
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When vancomycin is used but the bacteremia persists, high‐dose daptomycin (10 mg/kg/day), 
if the isolate is susceptible, in combination with another agent such as gentamicin 1 mg/kg IV 
every 8 h, rifampin 600 mg PO/IV daily, or 300–450 mg PO/IV twice daily, linezolid 600 mg 
PO/IV BID, TMP‐SMX 5 mg/kg IV twice daily should be considered. But in case of reduced 
susceptibility to vancomycin and daptomycin, quinupristin‐dalfopristin 7.5 mg/kg/dose IV 
every 8 h, TMP‐SMX 5 mg/kg/dose IV twice daily, linezolid 600 mg PO/IV twice daily, or 
telavancin 10 mg/kg/dose IV once daily may be other options.
11. Recommendations for vancomycin dosing
In case of bacteremia, the dose of IV vancomycin is 15–20 mg/kg/day divided in two or three 
doses in order to conserve normal renal function. For seriously ill patients such as those 
with sepsis, meningitis, pneumonia, or infective endocarditis with suspected MRSA infec‐
tion, a loading dose of 25–30 mg/kg (actual body weight) may be considered. Monitoring 
of vancomycin trough levels is necessary to guide the dosing of this antibiotic. Serum 
trough levels should be measured prior to the fourth or fifth dose. For serious infections 
such as bacteremia, infective endocarditis, meningitis, pneumonia, and necrotizing fasci‐
itis due to MRSA, vancomycin trough concentrations of 15–20 μg/mL are recommended. 
Vancomycin trough monitoring is recommended for serious infections, patients who are 
morbidly obese have renal dysfunction or have fluctuating volumes of distribution. For 
isolates with a vancomycin MIC ≤ 2, the patient’s clinical response should determine the 
continued use of vancomycin; however, if the patient has not had a clinical or microbio‐
logic response to vancomycin despite adequate debridement and removal of other foci of 
infection, an alternative to vancomycin is recommended regardless of MIC. For the isolates 
with a vancomycin MIC >2 μg/mL (e.g., VISA or VRSA), an alternative to vancomycin 
should be used.
12. Prevention
Decolonization is important to achieve prevention of S. aureus bacteremia and other infec‐
tions. The role of decolonization in controlling the spread of S. aureus is still unclear. It is also 
unclear what the optimal regimen is. Options include agents for nasal decolonization such as 
mupirocin and topical body decolonization with an agent such as chlorhexidine gluconate to 
target the extra nasal sites. Systemic oral antibiotics can be used for decolonization; however, 
there are issues that are very important to consider for decolonization, recolonization, and 
development of resistance. The current guidelines suggest that decolonization be considered 
in patients with recurrent skin infections or ongoing transmission occurring among house‐
hold contacts despite optimizing wound care and hygiene measures. Hand hygiene consists 
of soap and water or an alcohol‐based hand rub before and after contact with infected areas. 
Sharing personal items is discouraged.
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As for hospitals, infection control and prevention strategies should include hand hygiene, 
active surveillance to identify S. aureus colonization, and environmental cleaning. Patient 
bathing with chlorhexidine gluconate in intensive care units leads to a reduction in S. aureus 
colonization and infection. It is felt that bathing with chlorhexidine gluconate is a measure for 
source control that may lead to less contamination of health care worker hands, thus less con‐
tamination of the environment and the spread of infection to other patients. One additional 
infection control strategy for years has been to create a vaccination against S. aureus. So far, 
attempts have been unsuccessful, but there is much research in this area.
13. Future perspective
S. aureus has had a steady increase in incidence over the last several decades. The higher 
frequency of artificial catheters, cardiac devices, joints being placed, of skin and surgical site 
wounds becoming infected, and intervenous drug use all serve as nidi for infection, particu‐
larly bacteremia. The cost and resource burden on health care systems is projected to continue 
to grow as the number of risk factors increase. There is also the problem to consider of how 
MRSA initially was only seen in health care settings but now makes up a large percentage of 
community‐based infections.
What are some of the ways the medical community is working on not only treating but also 
preventing a much more widespread and resistant phenomenon? The approval of several 
newer antibiotics to combat serious MRSA infections shown in 2014, and there are a number 
of prospective antibiotics being studied with the potential to come to market [17]. A con‐
certed effort among medical centers to make improvements at the level of the diagnostic stage 
(using transesophageal imaging more regularly) will be necessary in order to improve out‐
comes. In a different approach, the relationship among host immunologic factors in conjunc‐
tion with environmental factors would be an additional avenue for exploration and possibly 
result in additional, nonantibiotic regimens. Continued use and awareness of infection pre‐
vention measures such as use of isolation inpatient and basic hand hygiene are both effective 
 strategies in the greater attempt to not allow the bacteria to morph any and to prevent basic 
spread of the organism. Finally, there may be a time in the future when the ultimate means of 
infection control—a vaccination—would become available.
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